Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Antoîne Italiano(Memorial Sloan Kettering Cancer Center), Vincent Ribrag(Institut Gustave Roussy), Eric Hedrick(Florida Hospital Cancer Institute), Andréa Varga(Institut Gustave Roussy), Carlo Lucchesi(Inserm), Alicia Clawson(Epizyme (United States)), Scott Ribich(Blueprint Medicines (United States)), Benjamin Suttle(Epizyme (United States)), Heike Keilhack(Epizyme (United States)), Mark Woodruff(Epizyme (United States)), Jean‐Marie Michot(Institut Gustave Roussy), Maud Toulmonde(Institut Bergonié), Peter Ho(Epizyme (United States)), Robert A. Copeland(Epizyme (United States)), Blythe Thomson(Epizyme (United States)), Jean‐Michel Coindre(Université de Bordeaux), Takashi Owa(Eisai (United States)), Stephen J. Blakemore(Epizyme (United States)), Alice McDonald(Millennium Engineering and Integration (United States)), Jean‐Charles Soria(Inserm)
Cited by 614
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k